Why Indian Pharma’s Shift to Innovation is Being Undervalued by Markets

The Indian pharmaceutical sector is undergoing a structural metamorphosis, moving away from its traditional identity as a "generics factory" toward becoming a global innovation powerhouse. While this transition is expected to drive significant value through 2035, analysts suggest that the stock market has yet to fully price in this fundamental change.

From Generic Manufacturing to the "Innovation Pyramid"

For decades, the valuation of Indian pharma companies was tied almost exclusively to their ability to manufacture and export off-patent generic drugs to the United States. However, Nandan Kulkarni, Director at Bernstein, argues that this playbook is becoming obsolete. Indian biopharma companies are now aggressively shifting capital allocation toward high-margin, complex segments.

This evolution is characterized by a move up the "innovation pyramid," where companies are focusing on:

Kulkarni notes that while the "Street" still models these companies as mere contract manufacturers with some US generics exposure, the actual boardroom conversations have shifted toward innovation pipelines and global specialty positioning.

The GLP-1 Revolution and Margin Expansion

A significant driver of this new era is the rise of GLP-1 drugs—the highly successful class of medications used for diabetes and obesity management. This shift presents a massive opportunity for Indian players to move up the value chain.

Currently, insulin is a staple in the market, but Kulkarni projects its market share could drop to approximately 50% by FY31 as GLP-1s offer superior glycemic control and weight management. For Indian biopharma, this is a net positive; while insulin is historically a lower-margin product, GLP-1s and peptides offer significantly higher gross margins. Although adoption in India may be slower than in North America due to socioeconomic factors, the long-term growth potential in the GLP-1 ecosystem—including diagnostics and obesity management—is substantial.

Realizing the "China Plus One" Strategy

While the "China plus one" narrative has been discussed for years without significant results, Kulkarni believes the current landscape is fundamentally different. Geopolitical tensions and the instability surrounding major players like WuXi have moved the industry from mere policy intent to active execution.

As global innovators and policymakers structurally realign their supply chains to reduce dependence on China, India’s deep expertise in biopharma makes it a primary beneficiary. Unlike previous years, the current shift in global supply chains is being executed in real-time, providing a structural tailwind for Indian manufacturers.

Key Takeaways